Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 66

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 66
---
 fair value through the profit and loss account.

The financial liability is valued using the either the Monte Carlo model or the
Black-Scholes option pricing model. Financial liabilities at FVTPL are stated at fair value, with any gains or losses arising on re-measurement
recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any interest paid on the financial liability
and is included in the ‘finance income’ or ‘finance expense’ lines item in the income statement. Fair value is
determined in the manner described in note19.

Other financial liabilities include the following items:

  Borrowings are initially recognised at fair value net of any                                                                                 

  Trade payables and other short-term monetary liabilities are                                                        

Share
capital

Financial instruments issued by the Group are classified as equity only to the extent
that they do not meet the definition of a financial liability or financial asset. The Group has three classes of share in existence:

  ordinary shares of £ 0.00005 each are classified as equity instruments;  

  ‘ A’ deferred shares of £ 1 each are classified as equity instruments;  

  ‘ B’ deferred shares of £ 0.001 each are classified as equity instruments;  

  ‘ C’ deferred shares of £ 0.00005 each are classified as equity instruments.  

Retirement
benefits: defined contribution schemes

Contributions to defined contribution pension schemes are charged to the consolidated
statement of comprehensive income in the year to which they relate.

Provisions

Provisions are recognised when the Group has a present obligation (legal or constructive)
as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation
and a reliable estimate can be made of the amount of the obligation.

Share-based
payments

The Group operates a number of equity-settled, share-based compensation plans, under
which the entity receives services from Directors and employees as consideration for equity instruments (options) of the Group. The fair
value of the Directors and employee services received in exchange for the grant of the options is recognised as an expense. The total
amount to be expensed is determined by reference to the fair value of the options granted:

  including any market performance conditions (including the share  

  excluding the impact of any service and non-market performance                                           

  including the impact of any non-vesting conditions (for example,  

Non-market performance and service conditions are included in assumptions about
the